Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

(MedPage Today) — ORLANDO — In a phase III trial with potential practice-changing implications, the non-covalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in chronic lymphocytic leukemia…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118892

Author :

Publish date : 2025-12-08 19:40:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

New Device Uses Steam to Kill Prostate Cancer

Related Posts

Super-Resolution Ultrasound Can Track Early Kidney Disease

Study: CTCL Increasing Among US Children, Young Adults

Why Children Still Get the Sleepier Allergy Drug

Vaping in cars with children could be banned under new plans

EPA Revokes Finding That Helped Fight Climate Change: Here’s What to Know

Bad Bunny Meets Public Health; Docs Are the Worst Patients; When Ortho Runs Rounds

Super-Resolution Ultrasound Can Track Early Kidney Disease

Study: CTCL Increasing Among US Children, Young Adults

Why Children Still Get the Sleepier Allergy Drug

Vaping in cars with children could be banned under new plans

EPA Revokes Finding That Helped Fight Climate Change: Here’s What to Know

Bad Bunny Meets Public Health; Docs Are the Worst Patients; When Ortho Runs Rounds

Potentially Blinding Eye Condition Tied to Ozempic Again

FDA Approves Wearable Device to Treat Pancreatic Cancer

Categories

Archives